Extension Study of Gelesis100 on Body Weight (GLOW-EX)

G

Gelesis

Status

Completed

Conditions

Overweight and Obesity

Treatments

Device: Gelesis100 (2.25 g)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03021291
GS-100-009

Details and patient eligibility

About

This study is designed to assess the effect of Gelesis100 on body weight after an additional exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least 3% weight loss, in the Gelesis Loss Of Weight GLOW, NCT02307279) study.

Enrollment

36 patients

Sex

All

Ages

22 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Completion of the GLOW study with at least 3% weight loss
  • Informed Consent Form signed by the subjects at the end of the GLOW study

Exclusion criteria

  • Pregnancy (or positive serum or urine pregnancy test(s) in females of childbearing potential) or lactation
  • Absence of medically approved contraceptive methods in females of childbearing potential (e.g., hysterectomy, non-oral contraceptive medications or intrauterine device combined with a barrier method, two combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are not acceptable contraceptive methods)
  • Subjects considering smoking cessation during the study
  • Subjects anticipating surgical intervention during the study
  • Significant intolerance to the study product during the GLOW study
  • Increase of ≥ 0.5% point (≥ 5.5 mmol/mol) in HbA1c from the Baseline Visit of the GLOW study in subjects with treated or untreated type 2 diabetes if considered clinically relevant, or any increase if HbA1c is > 8.5% (> 69 mmol/mol)
  • Increase of ≥ 10% in total cholesterol, low-density lipoprotein (LDL) cholesterol, or triglycerides from the Baseline Visit of the GLOW study in subjects with elevated lipids at the Baseline Visit of the GLOW study if considered clinically relevant, or any increase if serum LDL cholesterol is ≥ 190 mg/dL (≥ 4.93 mmol/L) and/or serum triglycerides are ≥ 500 mg/dL (≥ 5.65 mmol/L)
  • Increase of ≥ 10 mm Hg in supine systolic blood pressure (SBP) and/or supine diastolic blood pressure (DBP) from the Baseline Visit of the GLOW study in subjects with treated or untreated hypertension if considered clinically relevant, or any increase if supine SBP is > 160 mm Hg and/or supine DBP is > 95 mm Hg, based on the mean of two consecutive readings
  • Poor subject compliance with the GLOW study procedures and recommendations and/or major protocol deviation
  • Anticipated requirement for use of prohibited concomitant medications

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

36 participants in 1 patient group

Gelesis100
Experimental group
Description:
Gelesis100 (2.25 g) twice daily
Treatment:
Device: Gelesis100 (2.25 g)

Trial contacts and locations

16

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems